View Clinical Trial (Medical Research Study)
Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration
| City: |
|
Palo Alto |
| State: |
|
California |
| Zip Code: |
|
94303 |
| Conditions: |
|
Exudative Age-related Macular Degeneration |
| Purpose: |
|
Over the last several years, the standard of care for wet macular degeneration has become
treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as
frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor,
Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained
anatomic and visual improvement with many fewer injections (typically monthly injections for
3 months, followed by every-other-month injections, and as few as 5 injections a year). The
purpose of this study is to determine whether patients who have switched from ranibizumab to
VEGF Trap-Eye have comparable results.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Patients older than the age of 50 determined by a retinal physician at the Byers Eye
Institute at Stanford to have exudative AMD requiring treatment.
2. Patients with an established diagnosis of exudative AMD who have been maintained on a
regimen of intravitreal ranibizumab injections.
3. Postmenopausal or negative pregnancy test
4. Patients with an established diagnois of exidative AMD who have been switched from
intravitreal ranibizumab to intravitreal VEGF Trap-EYE.
Exclusion Criteria:
1. Patients with any previous or concurrent history of treatment of other retinal
diseases with pharmacologic agents other than ranibizumab, including verteporfin
photodynamic therapy, bevacizumab, triamcinolone, or dexamethasone.
2. Patients with prior history of vitrectomy surgery in the study eye.
3. Patients enrolled in any previous or current clinical trial or study of any
medication for AMD or any other retinal vascular disease, including diabetic
retinopathy or retinal vein occlusion.
4. Ocular media opacity precluding proper retinal imaging
5. Inadequate pupillary dilation to achieve proper retinal imaging
6. Concurrent use of systemic anti-VEGF agents
7. CNV due to other causes, including histoplasmosis, uveitis, trauma, or myopia
8. Active or recent (< 4 weeks) or recurrent inflammation in the eye
9. Current vitreous hemorrhage in the study eye limiting visualization of the fundus
10. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
11. Untreated glaucoma with IOP > 25 in the eye
12. Other ocular diseases that can compromise the visual acuity of the study eye such as
amblyopia and anterior ischemic optic neuropathy
13. Pregnancy or lactation
14. History of other disease, exam finding, or clinical laboratory that contraindicates
the use the drug
15. Current treatment for active systemic infection
16. Evidence of significant uncontrolled concomitant diseases such as cardiovascular
disease, pulmonary, renal, hepatic, endocrine, or GI disorders
17. History of recurrent significant infections or bacterial infections
18. Inability to comply with study or follow-up procedure
|
| NCT ID: |
|
NCT01526070 |
| Primary Contact: |
|
Theodore Leng, MD
Phone: 650-723-6995
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Palo Alto, California 94303
United States
Theodore Leng, MD
Phone: 650-723-6995
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 17, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|